Shots:
- Dana-Farber to receive up front & will be eligible to receive development and commercial milestones along with royalties on product sales
- SpringWorks has also entered into an SRA with Stanford Medicine & Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of EGFR to treat EGFR-mutant lung cancers & helps to support the lead optimization campaign and translational biology efforts
- The portfolio is designed to address de novo oncogenic drivers & emerging resistance mutations to EGFR inhibitors including multiple differentiated chemical series for targeting mutant EGFR and is currently in lead optimization & targets the C797S resistance mutation
Click here to read the full press release/ article | Ref: SpringWorks | Image: Businesswire
The post SpringWorks Enters into an Exclusive WW License Agreement with Academic Institutions to Advance Portfolio of Mutation-Selective EGFR Inhibitors first appeared on PharmaShots.
